1652 Stoklara Genel Bakış Bir yatırım holding şirketi olan Fusen Pharmaceutical Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünler araştırmakta ve geliştirmekte, üretmekte ve satmaktadır. Daha fazla detay
Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Fusen Pharmaceutical Company Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Fusen Pharmaceutical Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$0.80 52 Haftanın En Yüksek Seviyesi HK$1.39 52 Haftanın En Düşük Seviyesi HK$0.71 Beta 0.54 1 Aylık Değişim -13.04% 3 Aylık Değişim -20.00% 1 Yıllık Değişim -42.45% 3 Yıllık Değişim -34.96% 5 Yıllık Değişim -83.47% Halka arzdan bu yana değişim -68.50%
Son Haberler & Güncellemeler
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20 Daha fazla güncelleme görün
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20
Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617'' Jul 12
New minor risk - Market cap size Jun 27
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky May 21
Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024 Apr 28
CEO & Executive Director recently bought HK$224k worth of stock Apr 25 Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I) Apr 05
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27% Mar 31
Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022) Mar 30
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Oct 01
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Aug 31
Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023 Aug 18
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 Aug 13
Executive Chairman recently bought HK$84k worth of stock Apr 17
CEO & Executive Director recently bought HK$1.0m worth of stock Apr 01
Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021) Mar 30
Executive Chairman recently bought HK$1.1m worth of stock Jan 31
Executive Chairman recently bought HK$918k worth of stock Jan 10
CEO & Executive Director recently bought HK$375k worth of stock Jan 03
Executive Chairman recently bought HK$791k worth of stock Dec 19
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky Dec 14
Executive Chairman recently bought HK$2.3m worth of stock Nov 27
Less than half of directors are independent Nov 16
CEO & Executive Director recently bought HK$2.2m worth of stock Nov 10
Executive Chairman recently bought HK$2.0m worth of stock Nov 02
CEO & Executive Director recently bought HK$2.0m worth of stock Oct 25
CEO & Executive Director recently bought HK$658k worth of stock Oct 11
CEO & Executive Director recently bought HK$79k worth of stock Sep 22
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 14
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 10
First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021) Sep 02
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022 Aug 30
Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 Aug 21
Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022 Aug 17
CEO & Executive Director recently bought HK$157k worth of stock Aug 01
CEO & Executive Director recently bought HK$1.9m worth of stock Jul 15
CEO & Executive Director recently bought HK$1.9m worth of stock Jun 11
Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021 Jun 01
Less than half of directors are independent Apr 27
Investor sentiment improved over the past week Dec 22
CEO & Executive Director recently bought HK$856k worth of stock Dec 22
CEO & Executive Director recently bought HK$2.1m worth of stock Dec 12
Investor sentiment deteriorated over the past week Dec 07
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Sep 26
Investor sentiment deteriorated over the past week Sep 19
Investor sentiment improved over the past week Sep 03
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly Sep 02
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Aug 25
Investor sentiment deteriorated over the past week Jun 23
Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020 May 27
Investor sentiment deteriorated over the past week May 12
Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019) Apr 25
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly Apr 02
Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019) Apr 02
Investor sentiment improved over the past week Mar 29
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns Mar 06
New 90-day low: HK$4.17 Feb 24
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide Feb 08
Company Secretary has left the company Feb 03
Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021 Jan 31
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals? Jan 18
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet? Dec 28
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment deteriorated over the past week Dec 18
Investor sentiment deteriorated over the past week Dec 14
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition Dec 07
Market bids up stock over the past week Dec 07
New 90-day high: HK$6.00 Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns Nov 20
Market bids up stock over the past week Nov 05
New 90-day high: HK$4.69 Nov 03
Market bids up stock over the past week Oct 23
First half earnings released Sep 16
New 90-day high - HK$3.78 Sep 02
First half earnings released Sep 01
Fusen Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 31, 2020 Aug 22 Hissedar Getirileri 1652 HK Pharmaceuticals HK Pazar 7D -1.2% -4.0% -2.4% 1Y -42.4% -11.3% 16.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 1652 geçen yıl % -11.3 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 1652 geçen yıl % 16.2 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 1652's price volatile compared to industry and market? 1652 volatility 1652 Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 8.2% 10% most volatile stocks in HK Market 16.5% 10% least volatile stocks in HK Market 3.7%
İstikrarlı Hisse Senedi Fiyatı: 1652 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 1652 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir yatırım holding şirketi olan Fusen Pharmaceutical Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünler araştırmakta, geliştirmekte, üretmekte ve satmaktadır. Şirketin ürün portföyünde Shuanghuanglian oral solüsyonları ve Shuanghuanglian enjeksiyonlarını içeren Shuanghuanglian bazlı soğuk algınlığı ilaçları; ısı giderici ve detoksik oral solüsyonlar; nikardipin hidroklorür enjeksiyonları ve diğer ürünler bulunmaktadır. Ayrıca kardiyo serebrovasküler, kan basıncı ve şeker düşürücü, tonlayıcı, qi düzenleyici, anti-anemi, antibakteriyel ve anti-inflamatuar, gastrointestinal sistem ve balgam söktürücü öksürük kategorisinde ürünler sunmaktadır.
Daha fazla göster Fusen Pharmaceutical Company Limited Temel Bilgiler Özeti Fusen Pharmaceutical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 1652 temel i̇stati̇sti̇kler Piyasa değeri HK$591.44m Kazançlar(TTM ) -HK$95.54m Gelir(TTM ) HK$453.34m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 1652 gelir tablosu (TTM ) Gelir CN¥425.49m Gelir Maliyeti CN¥199.23m Brüt Kâr CN¥226.26m Diğer Giderler CN¥315.93m Kazançlar -CN¥89.67m
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -0.12 Brüt Marj 53.18% Net Kâr Marjı -21.08% Borç/Özkaynak Oranı 67.0%
1652 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/02 06:52 Gün Sonu Hisse Fiyatı 2025/01/02 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Fusen Pharmaceutical Company Limited 0 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Göster 0 daha fazla analist 
